Where can I buy Erdafitinib in China?

Erdafitinib (Erdafitinib), developed by Gensan Pharmaceuticals, is an oral pan-fibroblast growth factor receptor (FGFR) inhibitor. Erdafitinib has been shown to be effective in treating cancers with FGFR amplifications, mutations, and fusions, and is now approved for the treatment of patients with urothelial carcinoma whose tumors contain FGFR2 or FGFR3 mutations or fusions.

Before patients start treatment with erdafitinib, it is necessary to confirm that the tumor has sensitive fibroblast growth factor receptor (FGFR) genomic abnormalities (such as gene mutations, gene fusions). Because patients treated with erdafitinib often experience elevated phosphate concentrations, phosphate intake should not exceed 600-800 mg per day during treatment. Verify pregnancy status in females of reproductive potential before initiating treatment. Perform ophthalmic examinations, including visual acuity assessment, slit-lamp examination, fundoscopy, and optical coherence tomography, monthly during the first 4 months of erdafitinib treatment; every 3 months thereafter; and as clinically indicated (e.g., if new or worsening visual impairment occurs).

The original drug of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. Domestic patients cannot yet purchase this drug. The original version of erdafitinib currently sold in Hong Kong may cost more than 20,000 yuan per box of specifications 4 mg*14 tablets (the price may fluctuate due to exchange rates). Cheaper erdafitinib generic drugs produced by other pharmaceutical factories are also sold overseas. The drug ingredients are basically the same as those of the original drug. For example, the price of 4mg*60 tablets produced by a Bangladesh pharmaceutical factory may be more than 3,000 yuan per box (the price may fluctuate due to exchange rate effects). For more specific prices and drug information, please consult Yaode Medical Consultant.